Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
BACKGROUND
Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce.


METHODS
Subjects with virological success on first-PI-regimens who switched to NNRTI therapy (NNRTI group) or to nucleoside reverse transcriptase (NRTI)-only (NRTI group) were studied. The effect of the switch on the ongoing CD4+ trend was assessed by two-phase linear regression (TPLR), allowing us to evaluate whether a change in the CD4+ trend (hinge) occurred and the time of its occurrence. Furthermore, we described the evolution of the frequencies in CD4-count classes across four relevant time-points (baseline, before and immediately after the switch, and last visit). Finally, we explored whether the CD4+ counts evolved differently in patients who switched to NNRTI or NRTI-only regimens by considering: the overall CD4+ trends, the time to CD4+≥ 500/mm3 after the switch, and the area-under-the-curve (AUC) of the CD4+ after the switch.


RESULTS
Eight hundred and ninety-six patients, followed for a median of 2,121 days, were included. At TPLR, hinges occurred in 581/844 (68.9%), but in only 40/581 (6.9%) within a time interval (180 days) compatible with a possible relationship to the switch; furthermore, in 19/40 cases, CD4+ counts appeared to decrease after the hinges. In comparison with the NNRTI group, the NRTI group showed CD4+ count greater at baseline (P = 0.0234) and before the switch (P ≤ 0.0001), superior CD4+ T-cell increases after HAART was started, lower probability of not achieving CD4+ ≥ 500/mm3 (P = 0.0024), and, finally, no significant differences in the CD4+ T-cell AUC after the switch after adjusting for possible confounders (propensity score and pre-switch AUC). Persistence at CD4+ < 200/mm3 was observed in 34/435 (7.5%) patients, and a decrease below this level was found in only 10/259 (3.9%) with baseline CD4+ ≥ 350/mm3.


CONCLUSIONS
Switching from first-line PI to NNRTI- or NRTI-based regimens did not seem to impair CD4+ trend over long-term follow-up. Although the greater CD4+ increases in patients who switched to the NRTI-only regimen was due to higher CD4+ counts before the switch, several statistical analyses consistently showed that switching to this regimen did not damage the ongoing immune-reconstitution. Lastly, the observation that CD4+ T-cell counts remained low or decreased in the long term despite virological success merits further investigation.
University of Brescia, Italy. torti@med.unibs.it
Carlo
C
Torti
Antonella
A
d'Arminio-Monforte
Anton L
AL
Pozniak
Giuseppe
G
Lapadula
Giuliana
G
Cologni
Andrea
A
Antinori
Andrea
A
De Luca
Cristina
C
Mussini
Antonella
A
Castagna
Paola
P
Cicconi
Lorenzo
L
Minoli
Andrea
A
Costantini
Giampiero
G
Carosi
Hua
H
Liang
Bruno M
BM
Cesana
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D057915:Drug Substitution; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013995:Time
D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors
Stat Methods Med Res. 2008 Apr;17(2):141-50
17698930
JAMA. 1998 Jan 14;279(2):130-6
9440663
Clin Infect Dis. 2003 Aug 1;37(3):433-7
12884169
AIDS. 2003 May 2;17(7):963-9
12700445
Antivir Ther. 2006;11(5):609-18
16964829
AIDS Res Hum Retroviruses. 2009 Jun;25(6):756-76
19500017
Clin Infect Dis. 2008 Oct 15;47(8):1093-101
18783328
AIDS. 2001 Aug 17;15(12):1517-26
11504984
HIV Med. 2007 Apr;8(3):156-63
17461859
AIDS. 2008 Apr 23;22(7):841-8
18427202
J Antimicrob Chemother. 2005 Jul;56(1):190-5
15917286
AIDS. 2002 Feb 15;16(3):359-67
11834947
Arch Intern Med. 2010 Jan 11;170(1):57-65
20065200
AIDS. 2003 Nov 21;17(17):2451-9
14600516
AIDS. 2008 May 31;22(9):1039-46
18520347
N Engl J Med. 2008 May 15;358(20):2095-106
18480202
N Engl J Med. 2004 Apr 29;350(18):1850-61
15115831
Clin Pharmacol Ther. 2007 Sep;82(3):248-50
17700590
J Infect Dis. 2002 May 1;185(9):1251-60
12001042
Clin Infect Dis. 2010 May 1;50(9):1316-21
20297953
Antivir Ther. 2009;14(6):771-9
19812439
Clin Infect Dis. 2007 Feb 1;44(3):441-6
17205456
AIDS. 2002 Jan 25;16(2):245-9
11807309
Clin Infect Dis. 2002 Oct 15;35(8):1005-9
12355389
J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):229-36
11464141
N Engl J Med. 2003 Sep 11;349(11):1036-46
12968087
J Antimicrob Chemother. 2006 May;57(5):806-9
16531427
AIDS. 2006 May 12;20(8):1141-50
16691065
Lancet. 2008 Jul 26;372(9635):293-9
18657708
AIDS. 2003 Sep 5;17(13):1907-15
12960823
Antivir Ther. 2010;15(2):165-75
20386071
Lancet. 2007 Aug 4;370(9585):407-13
17659333
Clin Infect Dis. 2002 Feb 15;34(4):504-10
11797178
AIDS. 2006 Oct 24;20(16):2051-64
17053351